ASGE guideline: The role of endoscopy in acute non-variceal upper-GI hemorrhage

Douglas G. Adler, Jonathan A Leighton, Raquel E. Davila, R. David Hambrick, William K. Hirota, Brian C. Jacobson, Waqar A. Quereshi, Elizabeth Rajan, Marc J. Zuckerman, Robert D. Fanelli, Todd Baron, Douglas Orrick Faigel

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

For the following points: (A), prospective controlled trials; (B), observational studies; (C), expert opinion. • The initial management of UGIB is patient assessment and stabilization with volume resuscitation. (C) • High-risk patients are those with hematemesis, hemodynamic instability, coagulopathy, renal failure, older age, and multiple cormorbidities; these patients require more intensive monitoring. (B) • Antisecretory therapy with PPIs is recommended for patients with bleeding caused by peptic ulcers or in those with suspected peptic ulcer bleeding in whom endoscopy is delayed or unavailable. (A) • Preprocedure erythromycin improves mucosal visibility. (A) • While not part of the routine management of non-variceal UGIB, somatostatin or octreotide can reduce the risk of continued bleeding and the need for surgery but should be viewed as an adjunct to endoscopic and PPI therapy. (A) • Endoscopy is effective in the diagnosis and the treatment of UGIB. (A) • Endoscopic stigmata that predict a high risk of recurrent bleeding in PUD are active spurting, a visible vessel, and an adherent clot; these lesions should be treated. (A) • Patients with low-risk lesions can be considered for outpatient treatment. (A) • Available endoscopic treatment modalities include injection, cautery, and mechanical therapies. (A) • Studies have not demonstrated clear superiority of any one endoscopic treatment modality, although epinephrine injection alone is inferior to combination therapy for peptic ulcer bleeding. (A) • Scheduled repeat endoscopy in patients at high-risk for recurrent bleeding may be beneficial but its role has yet to be defined. (A) • Patients with PUD should be tested and treated for Helicobacter pylori. (A).

Original languageEnglish (US)
Pages (from-to)497-504
Number of pages8
JournalGastrointestinal Endoscopy
Volume60
Issue number4
StatePublished - Oct 2004

Fingerprint

Endoscopy
Guidelines
Hemorrhage
Peptic Ulcer
Therapeutics
Hematemesis
Cautery
Christianity
Injections
Octreotide
Expert Testimony
Erythromycin
Somatostatin
Helicobacter pylori
Resuscitation
Epinephrine
Observational Studies
Renal Insufficiency
Outpatients
Hemodynamics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Adler, D. G., Leighton, J. A., Davila, R. E., David Hambrick, R., Hirota, W. K., Jacobson, B. C., ... Faigel, D. O. (2004). ASGE guideline: The role of endoscopy in acute non-variceal upper-GI hemorrhage. Gastrointestinal Endoscopy, 60(4), 497-504.

ASGE guideline : The role of endoscopy in acute non-variceal upper-GI hemorrhage. / Adler, Douglas G.; Leighton, Jonathan A; Davila, Raquel E.; David Hambrick, R.; Hirota, William K.; Jacobson, Brian C.; Quereshi, Waqar A.; Rajan, Elizabeth; Zuckerman, Marc J.; Fanelli, Robert D.; Baron, Todd; Faigel, Douglas Orrick.

In: Gastrointestinal Endoscopy, Vol. 60, No. 4, 10.2004, p. 497-504.

Research output: Contribution to journalArticle

Adler, DG, Leighton, JA, Davila, RE, David Hambrick, R, Hirota, WK, Jacobson, BC, Quereshi, WA, Rajan, E, Zuckerman, MJ, Fanelli, RD, Baron, T & Faigel, DO 2004, 'ASGE guideline: The role of endoscopy in acute non-variceal upper-GI hemorrhage', Gastrointestinal Endoscopy, vol. 60, no. 4, pp. 497-504.
Adler DG, Leighton JA, Davila RE, David Hambrick R, Hirota WK, Jacobson BC et al. ASGE guideline: The role of endoscopy in acute non-variceal upper-GI hemorrhage. Gastrointestinal Endoscopy. 2004 Oct;60(4):497-504.
Adler, Douglas G. ; Leighton, Jonathan A ; Davila, Raquel E. ; David Hambrick, R. ; Hirota, William K. ; Jacobson, Brian C. ; Quereshi, Waqar A. ; Rajan, Elizabeth ; Zuckerman, Marc J. ; Fanelli, Robert D. ; Baron, Todd ; Faigel, Douglas Orrick. / ASGE guideline : The role of endoscopy in acute non-variceal upper-GI hemorrhage. In: Gastrointestinal Endoscopy. 2004 ; Vol. 60, No. 4. pp. 497-504.
@article{686dad7d5c304ebd8d13fc813f297bfa,
title = "ASGE guideline: The role of endoscopy in acute non-variceal upper-GI hemorrhage",
abstract = "For the following points: (A), prospective controlled trials; (B), observational studies; (C), expert opinion. • The initial management of UGIB is patient assessment and stabilization with volume resuscitation. (C) • High-risk patients are those with hematemesis, hemodynamic instability, coagulopathy, renal failure, older age, and multiple cormorbidities; these patients require more intensive monitoring. (B) • Antisecretory therapy with PPIs is recommended for patients with bleeding caused by peptic ulcers or in those with suspected peptic ulcer bleeding in whom endoscopy is delayed or unavailable. (A) • Preprocedure erythromycin improves mucosal visibility. (A) • While not part of the routine management of non-variceal UGIB, somatostatin or octreotide can reduce the risk of continued bleeding and the need for surgery but should be viewed as an adjunct to endoscopic and PPI therapy. (A) • Endoscopy is effective in the diagnosis and the treatment of UGIB. (A) • Endoscopic stigmata that predict a high risk of recurrent bleeding in PUD are active spurting, a visible vessel, and an adherent clot; these lesions should be treated. (A) • Patients with low-risk lesions can be considered for outpatient treatment. (A) • Available endoscopic treatment modalities include injection, cautery, and mechanical therapies. (A) • Studies have not demonstrated clear superiority of any one endoscopic treatment modality, although epinephrine injection alone is inferior to combination therapy for peptic ulcer bleeding. (A) • Scheduled repeat endoscopy in patients at high-risk for recurrent bleeding may be beneficial but its role has yet to be defined. (A) • Patients with PUD should be tested and treated for Helicobacter pylori. (A).",
author = "Adler, {Douglas G.} and Leighton, {Jonathan A} and Davila, {Raquel E.} and {David Hambrick}, R. and Hirota, {William K.} and Jacobson, {Brian C.} and Quereshi, {Waqar A.} and Elizabeth Rajan and Zuckerman, {Marc J.} and Fanelli, {Robert D.} and Todd Baron and Faigel, {Douglas Orrick}",
year = "2004",
month = "10",
language = "English (US)",
volume = "60",
pages = "497--504",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - ASGE guideline

T2 - The role of endoscopy in acute non-variceal upper-GI hemorrhage

AU - Adler, Douglas G.

AU - Leighton, Jonathan A

AU - Davila, Raquel E.

AU - David Hambrick, R.

AU - Hirota, William K.

AU - Jacobson, Brian C.

AU - Quereshi, Waqar A.

AU - Rajan, Elizabeth

AU - Zuckerman, Marc J.

AU - Fanelli, Robert D.

AU - Baron, Todd

AU - Faigel, Douglas Orrick

PY - 2004/10

Y1 - 2004/10

N2 - For the following points: (A), prospective controlled trials; (B), observational studies; (C), expert opinion. • The initial management of UGIB is patient assessment and stabilization with volume resuscitation. (C) • High-risk patients are those with hematemesis, hemodynamic instability, coagulopathy, renal failure, older age, and multiple cormorbidities; these patients require more intensive monitoring. (B) • Antisecretory therapy with PPIs is recommended for patients with bleeding caused by peptic ulcers or in those with suspected peptic ulcer bleeding in whom endoscopy is delayed or unavailable. (A) • Preprocedure erythromycin improves mucosal visibility. (A) • While not part of the routine management of non-variceal UGIB, somatostatin or octreotide can reduce the risk of continued bleeding and the need for surgery but should be viewed as an adjunct to endoscopic and PPI therapy. (A) • Endoscopy is effective in the diagnosis and the treatment of UGIB. (A) • Endoscopic stigmata that predict a high risk of recurrent bleeding in PUD are active spurting, a visible vessel, and an adherent clot; these lesions should be treated. (A) • Patients with low-risk lesions can be considered for outpatient treatment. (A) • Available endoscopic treatment modalities include injection, cautery, and mechanical therapies. (A) • Studies have not demonstrated clear superiority of any one endoscopic treatment modality, although epinephrine injection alone is inferior to combination therapy for peptic ulcer bleeding. (A) • Scheduled repeat endoscopy in patients at high-risk for recurrent bleeding may be beneficial but its role has yet to be defined. (A) • Patients with PUD should be tested and treated for Helicobacter pylori. (A).

AB - For the following points: (A), prospective controlled trials; (B), observational studies; (C), expert opinion. • The initial management of UGIB is patient assessment and stabilization with volume resuscitation. (C) • High-risk patients are those with hematemesis, hemodynamic instability, coagulopathy, renal failure, older age, and multiple cormorbidities; these patients require more intensive monitoring. (B) • Antisecretory therapy with PPIs is recommended for patients with bleeding caused by peptic ulcers or in those with suspected peptic ulcer bleeding in whom endoscopy is delayed or unavailable. (A) • Preprocedure erythromycin improves mucosal visibility. (A) • While not part of the routine management of non-variceal UGIB, somatostatin or octreotide can reduce the risk of continued bleeding and the need for surgery but should be viewed as an adjunct to endoscopic and PPI therapy. (A) • Endoscopy is effective in the diagnosis and the treatment of UGIB. (A) • Endoscopic stigmata that predict a high risk of recurrent bleeding in PUD are active spurting, a visible vessel, and an adherent clot; these lesions should be treated. (A) • Patients with low-risk lesions can be considered for outpatient treatment. (A) • Available endoscopic treatment modalities include injection, cautery, and mechanical therapies. (A) • Studies have not demonstrated clear superiority of any one endoscopic treatment modality, although epinephrine injection alone is inferior to combination therapy for peptic ulcer bleeding. (A) • Scheduled repeat endoscopy in patients at high-risk for recurrent bleeding may be beneficial but its role has yet to be defined. (A) • Patients with PUD should be tested and treated for Helicobacter pylori. (A).

UR - http://www.scopus.com/inward/record.url?scp=4744375398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4744375398&partnerID=8YFLogxK

M3 - Article

C2 - 15472669

AN - SCOPUS:4744375398

VL - 60

SP - 497

EP - 504

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 4

ER -